AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Pantothenate Kinase-Associated Neurodegeneration (PKAN)

Recent research efforts aimed at curing Pantothenate Kinase-Associated Neurodegeneration (PKAN).

Last updated

Pantothenate Kinase-Associated Neurodegeneration (PKAN)

Overview

Pantothenate Kinase-Associated Neurodegeneration (PKAN) is an ultra-rare, inherited neurodegenerative disorder and the most common form of neurodegeneration with brain iron accumulation (NBIA). It results from two disease-causing copies of the PANK2 gene, which normally encodes an enzyme needed for production of coenzyme A (CoA), a molecule essential to cellular energy and lipid metabolism. PKAN causes progressive movement problems—especially dystonia, or sustained involuntary muscle contractions—along with rigidity, speech and swallowing difficulty, and sometimes retinal degeneration and vision loss. The classic form generally begins in early childhood and progresses faster; a later-onset atypical form can progress more slowly. GeneReviews: PKAN (ncbi.nlm.nih.gov)

There is currently no approved treatment that corrects the underlying PANK2 defect or stops PKAN progression. Standard care is therefore multidisciplinary and symptom-focused: medications, physical/occupational/speech therapy, nutritional and respiratory support when needed, and, for selected people with severe dystonia, deep-brain stimulation (DBS) of the internal globus pallidus. In early-onset disease, loss of independent walking commonly occurs during adolescence, although severity and rate of progression vary substantially between individuals. GeneReviews: PKAN Long-term DBS outcomes (ncbi.nlm.nih.gov)

Scope of Recent Research (2020–present)

Since 2020, PKAN research has become more mechanistically focused and more translational, concentrating on restoring CoA production downstream of defective PANK2, activating alternative pantothenate-kinase enzymes, replacing PANK2 through gene therapy, and developing biomarkers that can make small rare-disease trials more informative. The field has credible disease-modifying hypotheses and one active preclinical gene-therapy program, but no approach has yet demonstrated reversal or prevention of human PKAN; a curative therapy remains preclinical. PKAN treatment redesign PKAN gene-therapy update (pmc.ncbi.nlm.nih.gov)

Major Breakthroughs and Emerging Therapies

The most advanced disease-targeted clinical strategy has been metabolic bypass therapy. PANK2 normally converts vitamin B5–derived compounds into phosphopantothenate, an early CoA-building-block; supplying a downstream metabolite could potentially bypass the blocked step. Fosmetpantotenate (RE-024) was designed for this purpose, but its randomized controlled trial did not improve the PKAN Activities of Daily Living score versus placebo at 24 weeks, and its development program was discontinued. This negative result was important because it showed that simply delivering a phosphopantothenate replacement candidate does not necessarily translate into measurable clinical benefit. Fosmetpantotenate randomized trial (pmc.ncbi.nlm.nih.gov)

A related bypass approach uses 4′-phosphopantetheine, called CoA-Z in clinical development. In laboratory models, this metabolite can enter the CoA pathway downstream of PANK2; earlier work found correction of CoA, iron-handling, dopamine-related, and mitochondrial abnormalities in mammalian PKAN models. The North American CoA-Z study was designed primarily around safety, tolerability, laboratory measures, and CoASY messenger RNA, rather than demonstrating a cure or a definitive effect on long-term clinical progression. 4′-Phosphopantetheine in PKAN models CoA-Z trial record (pubmed.ncbi.nlm.nih.gov)

Researchers are also developing oral, cell-penetrant phosphopantothenate prodrugs. A 2020 preclinical study reported cyclic phosphopantothenic-acid prodrugs that regenerated CoA in a PANK-deficient cellular system and delivered the active metabolite to mouse brain after oral dosing. These compounds remain experimental: evidence of brain exposure and biochemical pathway engagement is encouraging, but human safety, dosing, and clinical efficacy have not been established. Cyclic phosphopantothenate prodrugs (pubmed.ncbi.nlm.nih.gov)

A second strategy is to compensate for missing PANK2 by activating PANK3, a related enzyme that can also support CoA synthesis. Virtus Therapeutics received a $796,801 NIH/NINDS Small Business Innovation Research award for PANK3 activators; its grant abstract reports nanomolar PANK3 activators with brain exposure in mice and planned testing in PANK2-deficient cells and mouse models. This is an attractive oral-drug concept, but it faces a key biological question: whether increasing CoA production through PANK3 outside mitochondria can adequately repair the brain-region-specific effects of mitochondrial PANK2 deficiency. NIH SBIR award: PANK activators PKAN treatment redesign (sbir.gov)

Gene replacement is the most explicitly curative-oriented program. Oregon Health & Science University (OHSU) and the Horae Gene Therapy Center at UMass Chan Medical School are developing an adeno-associated virus serotype 9 (AAV9) vector carrying full-length human PANK2. As of the March 18, 2026 project update, the team had completed proof-of-concept and durability studies in PKAN mice, refined the delivery vector, held an FDA INTERACT meeting, submitted a pre-investigational-new-drug package, and was planning toxicology studies and clinical-trial design. This is promising progress, but it is not yet a human trial, and no animal efficacy dataset sufficient to establish durable functional rescue has been publicly reported. PKAN gene-therapy update (nbiacure.org)

Clinical Trials and Experimental Approaches

The pivotal randomized fosmetpantotenate study, sponsored by Retrophin, was a placebo-controlled trial in genetically confirmed PKAN. It failed its primary 24-week efficacy comparison: the least-squares mean difference in PKAN Activities of Daily Living change was −0.09 points between fosmetpantotenate and placebo. The result underscores that biochemical rationale alone is not enough and that future trials need sensitive measures capable of distinguishing a true slowing of progression from day-to-day variation in severe dystonia and disability. Fosmetpantotenate randomized trial (pmc.ncbi.nlm.nih.gov)

CoA-Z is listed as a Phase 2 OHSU-led randomized, double-blind, placebo-controlled crossover study followed by an open-label treatment phase. The study enrolled people with PKAN from North America and evaluated adverse events, laboratory abnormalities, adherence, and CoASY messenger RNA expression; the initial blinded and open-label arms met enrollment goals. The public registry does not provide peer-reviewed efficacy outcomes, so CoA-Z should not yet be characterized as clinically disease-modifying or curative. CoA-Z trial record CoA-Z trial protocol (clinicaltrials.gov)

No human PANK2 gene-replacement, gene-editing, RNA-therapy, or cell-therapy trial was identified in the reviewed sources as of August 8, 2026. The leading gene-replacement effort remains in vector optimization, toxicology preparation, and regulatory planning. PKAN gene-therapy update (nbiacure.org)

Methodologies and Scientific Approaches

PKAN investigators combine patient-derived cells, engineered mouse models, biochemical assays, and longitudinal natural-history studies. A 2020 conditional mouse model that removed neuronal Pank2 together with systemic Pank1 developed central-nervous-system CoA deficiency, abnormal movement, reduced short-chain acyl-CoAs, altered gene expression, and reduced brain heme, providing a platform for testing CoA-restoration and enzyme-activation treatments. PANK-deficient mouse model (pmc.ncbi.nlm.nih.gov)

Biomarker development is increasingly important because PKAN trials enroll very few participants and progression is variable. Current approaches include MRI evidence of basal-ganglia iron, clinical dystonia and function scales, residual PANK2 activity in patient red blood cells, CoA-pathway metabolites, and serum metabolomics. A 2025 serum metabolomics and metallomics study reported patterns consistent with ferroptosis—iron-dependent lipid damage—in people with PKAN, supporting further investigation of oxidative lipid injury as both a disease mechanism and a possible pharmacodynamic biomarker. OHSU’s five-year PKANready natural-history study is intended to define symptom trajectories and improve endpoints for future interventional studies. Residual PANK2 activity study PKAN metabolomics study PKANready (pubmed.ncbi.nlm.nih.gov)

Leading Institutions and Funding

OHSU’s NBIA research program, led by investigators including Susan Hayflick and colleagues, is a central driver of PKAN natural-history work, CoA-Z development, mouse-model research, and the emerging PANK2 gene-therapy program. The CoA-Z Phase 2 protocol identifies NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development as sponsor, with additional support from the Spoonbill Foundation; OHSU is the study center, with collaborators at Oregon State University and Washington State University. CoA-Z trial protocol (cdn.clinicaltrials.gov)

The gene-therapy program joins OHSU with UMass Chan Medical School’s Horae Gene Therapy Center and is supported through the OHSU Foundation, the Loving Loic Foundation, and collaboration with the NBIA Disorders Association. On the small-molecule side, Virtus Therapeutics received a $796,801 NIH/NINDS SBIR award for PANK3-activator development, reflecting federal investment in a potentially scalable oral treatment approach. PKAN gene-therapy update NIH SBIR award: PANK activators (nbiacure.org)

Strengths, Limitations, and Challenges

PKAN research has a major advantage: it is a single-gene disorder with a well-defined enzymatic defect and multiple plausible ways to intervene upstream of neurodegeneration. Metabolic bypass, PANK3 activation, and PANK2 gene replacement address the cause more directly than symptomatic therapy does. Better disease models, biochemical readouts, and natural-history data are also making it more feasible to test whether a treatment changes biology before irreversible neuronal injury occurs. PANK-deficient mouse model PKANready (pmc.ncbi.nlm.nih.gov)

The limitations are substantial. The failed fosmetpantotenate trial demonstrates the difficulty of translating restoration of a metabolite into meaningful functional benefit. For gene therapy, critical unanswered questions include safe and sufficiently broad delivery to vulnerable brain cells, the required dose and distribution, durability, immune responses to AAV, and whether treatment can rescue neurons after established degeneration. Small-molecule activators must prove that they safely restore the right CoA pools in the right cells, not merely raise a laboratory measurement. Ultra-rare disease prevalence also makes recruitment, endpoint validation, long follow-up, manufacturing, and equitable access unusually challenging. Fosmetpantotenate randomized trial PKAN treatment redesign PKAN gene-therapy update (pmc.ncbi.nlm.nih.gov)

Outlook and Future Directions

PKAN is not close to a proven cure as of August 8, 2026, but the field is closer to cause-directed treatment than it was at the start of this decade. The most important milestones to watch are publication of the full CoA-Z clinical dataset; advancement of selective, brain-penetrant PANK3 activators into formal candidate selection and human testing; validation of metabolomic and functional biomarkers; and, most importantly, completion of gene-therapy toxicology studies and FDA clearance of a first-in-human PANK2 gene-replacement trial. A durable cure will require evidence not only that a therapy reaches the brain and restores PANK2 or CoA biology, but also that it safely preserves function or changes the long-term course of disease. CoA-Z trial record PKAN gene-therapy update NIH SBIR award: PANK activators (clinicaltrials.gov)

References

Don't see your disease? Request a report